ALEC vs GALT
ALEC: An early-stage biotech company developing novel therapeutic candidates for neurodegenerative diseases through preclinical research and clinical trials. GALT: Clinical-stage biopharmaceutical company developing galectin-3 inhibitors derived from plant carbohydrates to treat liver fibrosis, cirrhosis, and cancer.
Side-by-side fundamentals
| Metric | ALEC | GALT | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $1.53 | $3.50 | |
| Market cap as of 2026-07-23 | $169M | $253M | |
| Net margin as of 2026-07-23 | -680.8% | n/a | |
| Operating margin as of 2026-07-23 | -739.7% | n/a | |
| ROE as of 2026-07-23 | -295.2% | -258.6% | GALT higher |
| ROA as of 2026-07-23 | -40.9% | -164.7% | ALEC higher |
| Debt / equity as of 2026-07-23 | 0.94 | 11.09 | ALEC lower |
| Revenue growth (YoY) as of 2026-07-23 | -79.2% | n/a | |
| Revenue CAGR (3y) SEC XBRL | -46.0% | n/a | |
| Beta as of 2026-07-23 | 0.57 | 0.36 | |
| 1-year return as of 2026-07-22 close | -11.0% | +22.4% | GALT higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.